213 related articles for article (PubMed ID: 25426077)
1. Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.
Burghaus R; Coboeken K; Gaub T; Niederalt C; Sensse A; Siegmund HU; Weiss W; Mueck W; Tanigawa T; Lippert J
Front Physiol; 2014; 5():417. PubMed ID: 25426077
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
3. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
5. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
7. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
8. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
10. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
11. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Coleman CI; Tangirala M; Evers T
PLoS One; 2016; 11(6):e0157769. PubMed ID: 27327275
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
13. Medication Error When Switching from Warfarin to Rivaroxaban Leading to Spontaneous Large Ecchymosis of the Abdominal and Chest Wall.
Egger F; Targa F; Unterholzner I; Grant RP; Herrmann M; Wiedermann CJ
Clin Pract; 2016 Aug; 6(3):873. PubMed ID: 27777713
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban for the treatment and prevention of thromboembolic disease.
Antoniou S
J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
[TBL] [Abstract][Full Text] [Related]
17. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
18. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
19. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Mangiafico RA; Mangiafico M
Curr Med Chem; 2012; 19(27):4688-98. PubMed ID: 22830344
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
